Skip to main content
TipRanks
Go Ultimate75% OFF

Sinovac Biotech (SVA) Stock Price & Analysis

137 Followers

SVA Stock Chart & Stats

$6.47$0.00(0.00%)
At close: 4:00 PM EST
$6$6.25$6.5Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$6.25 - $6.58
52-Week Range
$6.25 - $6.58
Previous Close
$6.47
Volume
N/A
Average Volume (3M)
8,227
Market Cap
$460.27M
Enterprise Value
$429.15M
Total Cash (Recent Filing)
$11.22B
Total Debt (Recent Filing)
$298.98M
Price to Earnings (P/E)
―
Beta
N/A
Next Earnings
May 03, 2027 (Est.)
EPS Estimate
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

International Revenue Expansion

Rapid overseas growth is diversifying Sinovac beyond its domestic base and improving the revenue mix. Expansion across international markets can create a broader commercial platform for existing and newly approved vaccines, supporting more durable growth over the next several quarters.

Vaccine Portfolio And Pipeline

New approvals and late-stage vaccine candidates broaden the portfolio beyond established products and create additional avenues for future commercialization. Progress in rabies, enterovirus, PCV13 and meningococcal vaccines strengthens the company’s longer-term product renewal potential.

Gross Margin And Conservative Leverage

A high gross margin indicates that the vaccine portfolio retains attractive product economics, while low leverage limits debt-related pressure on the business. Together, these characteristics provide financial flexibility to support research, commercialization and international expansion.

Bears Say

Persistent Losses And Cash Burn

Deeply negative operating and free cash flow materially weaken Sinovac’s ability to fund operations and development internally. Continued cash burn, alongside recurring net losses, could force greater reliance on existing balance-sheet resources and constrain investment flexibility.

Weak And Volatile Earnings Power

The post-2021 decline shows that exceptional pandemic-era demand did not translate into consistently durable earnings power. Although revenue has stabilized and gross margins remain solid, ongoing operating losses make profitability recovery uncertain and increase execution pressure.

Governance And Filing Compliance Overhang

Ongoing regulatory monitoring and board-related litigation create governance and execution risks that can distract management from commercial priorities. Any repeat filing failure or unresolved control dispute could undermine stakeholder confidence and complicate the company’s strategic progress.

Sinovac Biotech News

SVA FAQ

What was Sinovac Biotech’s price range in the past 12 months?
Sinovac Biotech lowest stock price was $6.25 and its highest was $6.58 in the past 12 months.
What is Sinovac Biotech’s market cap?
Sinovac Biotech’s market cap is $460.27M.
When is Sinovac Biotech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Sinovac Biotech’s earnings last quarter?
Sinovac Biotech released its earnings results on Aug 17, 2026. The company reported -$0.838 earnings per share for the quarter.
Is Sinovac Biotech overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Sinovac Biotech pay dividends?
Sinovac Biotech pays a dividend of $55 which represents an annual dividend yield of ―. See more information on Sinovac Biotech dividends here
What is Sinovac Biotech’s EPS estimate?
Sinovac Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinovac Biotech have?
Sinovac Biotech has 71,860,700 shares outstanding.
What happened to Sinovac Biotech’s price movement after its last earnings report?
Sinovac Biotech reported an EPS of -$0.838 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sinovac Biotech?
Currently, no hedge funds are holding shares in SVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology